Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Toxicity criteria]

H Furue1

  • 1Fourth Dept. of Internal Medicine, Teikyo University, Kawasaki, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 1, 1995
PubMed
Summary
This summary is machine-generated.

The Japan Society of Cancer Therapy (JSCT) toxicity criteria require revision due to outdated standards and inconsistencies. Updated criteria should incorporate quality of life and psychosocial factors for comprehensive patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Processing of CD109 by furin and its role in the regulation of TGF-beta signaling.

Oncogene·2010
Same author

Responses to 5-HT in morphologically identified neurons in the rat substantia gelatinosa in vitro.

Neuroscience·2009
Same author

Action of neuropeptide Y on nociceptive transmission in substantia gelatinosa of the adult rat spinal dorsal horn.

Neuroscience·2005
Same author

[Anti-nociceptive effect of calcitonin on chronic pain associated with osteoporosis].

Clinical calcium·2005
Same author

Functional reorganization of the spinal pain pathways in developmental and pathological conditions.

Novartis Foundation symposium·2004
Same author

Analysis of receptive fields revealed by in vivo patch-clamp recordings from dorsal horn neurons and in situ intracellular recordings from dorsal root ganglion neurons.

Life sciences·2004
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Clinical Trial Methodology
  • Pharmacovigilance

Context:

  • Cancer therapy toxicity assessment is crucial for patient safety and treatment efficacy.
  • Major cooperative study groups like WHO, ECOG, NCI (USA), and JCOG have significantly revised their toxicity criteria over the past decade.
  • The Japan Society of Cancer Therapy (JSCT) has not updated its toxicity criteria for over ten years, leading to potential inconsistencies.

Purpose:

  • To review and compare the JSCT toxicity criteria with those of international standards (WHO, ECOG, NCI, JCOG).
  • To identify inconsistencies and lack of clarity in the current JSCT toxicity grading system.
  • To advocate for the revision of JSCT toxicity criteria and the inclusion of broader assessment parameters.

Summary:

  • A review of JSCT toxicity criteria revealed significant outdatedness and inconsistencies compared to international standards.

Related Experiment Videos

  • The current JSCT criteria lack distinct grading and do not adequately address long-term complications, quality of life, or psychosocial aspects.
  • Revision is recommended to align JSCT criteria with global practices and enhance patient care through comprehensive toxicity assessment.

    • Impact:

    • Updating JSCT toxicity criteria will improve the standardization and accuracy of adverse event reporting in Japanese cancer clinical trials.
    • Incorporating quality of life and psychosocial factors will lead to a more holistic approach to patient management and supportive care.
    • Establishing standard criteria for long-term complications and identifying toxicity risk factors will enhance patient safety and optimize cancer treatment outcomes.